Pharma Lauds Brexit ‘Breakthrough’ But Says Focus Now Must Be On Drug Regulation & Supply
Executive Summary
The UK pharmaceutical industry has welcomed the announcement that Brexit talks are to move on to trade deal discussions, but says a regulatory cooperation agreement and a fixed transition period are essential to safeguard European supply chains. Several pharma executives outlined some of their key concerns at a parliamentary committee hearing on Dec. 5.
You may also be interested in...
GSK Adds £50m Per Year To Brexit Cost Estimates
Brexit is likely to cost GSK around £50m a year in the form of customs duties and transaction and administration costs. It is one of a handful of companies to have made its cost estimates public.
UK Pharma Execs Urged To Be More Outspoken About Brexit ‘Disaster’
Pharmaceutical executives from GSK, Sanofi and the UK generic medicines industry body giving evidence on the likely effects of Brexit on the UK life sciences sector at a recent parliamentary committee hearing were asked why they have not been more outspoken about their concerns.
Pharma Execs Flag Up More Brexit Regulatory Woes – And A Possible Solution
Pharma executives painted a rather bleak picture of a UK regulatory system cast adrift by a hard Brexit, with problems likely in areas such as drug approvals, clinical trials and the role of the MHRA. One solution was proposed, however, to avoid the need for a free-standing UK approvals system for new drugs.